These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 27576282)

  • 1. [Heparin-induced thrombocytopenia. New therapeutical options].
    Seculini Patiño CE; Tabares AH
    Medicina (B Aires); 2016; 76(4):230-4. PubMed ID: 27576282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful treatment with fondaparinux in heparin-induced thrombocytopenia and thrombosis].
    Seculini Patiño CE; Pascualini MF; Tabares AH
    Medicina (B Aires); 2015; 75(5):307-10. PubMed ID: 26502466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting oral anticoagulants as emerging treatment options for heparin-induced thrombocytopenia.
    Miyares MA; Davis KA
    Ann Pharmacother; 2015 Jun; 49(6):735-9. PubMed ID: 25855702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of heparin-induced thrombocytopenia.
    Greinacher A
    Thromb Haemost; 1999 Aug; 82(2):457-67. PubMed ID: 10605737
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia.
    Fabris F; Luzzatto G; Soini B; Ramon R; Scandellari R; Randi ML; Girolami A
    J Intern Med; 2002 Aug; 252(2):149-54. PubMed ID: 12190890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-induced thrombocytopenia: diagnosis and management.
    Liebman HA
    Vascular; 2008; 16 Suppl 1():S71-6. PubMed ID: 18544310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The identification and management of heparin-induced thrombocytopenia in the vascular patient.
    LaMuraglia GM; Houbballah R; Laposata M
    J Vasc Surg; 2012 Feb; 55(2):562-70. PubMed ID: 22188737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients.
    Chang JJ; Parikh CR
    Semin Dial; 2006; 19(4):297-304. PubMed ID: 16893407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia.
    Nazy I; Clare R; Staibano P; Warkentin TE; Larché M; Moore JC; Smith JW; Whitlock RP; Kelton JG; Arnold DM
    J Thromb Haemost; 2018 Jul; 16(7):1402-1412. PubMed ID: 29723924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on heparin-induced thrombocytopenia: diagnosis and management.
    Bakchoul T
    Expert Opin Drug Saf; 2016 Jun; 15(6):787-97. PubMed ID: 26966871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunobiology of heparin-induced thrombocytopenia.
    Sandset PM
    Curr Top Microbiol Immunol; 2010; 341():193-202. PubMed ID: 20369319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.
    Arepally GM; Padmanabhan A
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):141-152. PubMed ID: 33267665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of heparin-induced thrombocytopenia.
    Donovan JL; Tran MT; Kanaan AO
    J Pharm Pract; 2010 Jun; 23(3):226-34. PubMed ID: 21507818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779-781).
    Schindewolf M; Lindhoff-Last E
    Thromb Haemost; 2008 Jul; 100(1):168-9; author reply 169-70. PubMed ID: 18612559
    [No Abstract]   [Full Text] [Related]  

  • 15. Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia.
    Levy JH; Tanaka KA; Hursting MJ
    Anesth Analg; 2007 Sep; 105(3):570-82. PubMed ID: 17717208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia.
    Legnani C; Cini M; Pili C; Boggian O; Frascaro M; Palareti G
    Thromb Haemost; 2010 Aug; 104(2):402-9. PubMed ID: 20539902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-induced thrombocytopenia, a prothrombotic disease.
    Levy JH; Hursting MJ
    Hematol Oncol Clin North Am; 2007 Feb; 21(1):65-88. PubMed ID: 17258119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group.
    Joseph J; Rabbolini D; Enjeti AK; Favaloro E; Kopp MC; McRae S; Pasalic L; Tan CW; Ward CM; Chong BH
    Med J Aust; 2019 Jun; 210(11):509-516. PubMed ID: 31155728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.
    Hess CN; Becker RC; Alexander JH; Lopes RD
    J Thromb Thrombolysis; 2012 Nov; 34(4):552-61. PubMed ID: 22843169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer.
    Sandset PM
    Thromb Res; 2012 Apr; 129 Suppl 1():S97-100. PubMed ID: 22682144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.